心誠鎂行動醫電由一群經驗豐富、胸懷呼吸治療創新願景的專業團隊於2014年成立。憑藉領先的技術與優秀的策略，心誠鎂除陸續取得美國、台灣、日本等知名投資人的支持。2019年9月，心誠鎂成為全球首批受邀進駐由阿斯特捷利康支持的無錫國家生命科學創新園，確立心誠鎂在呼吸藥物遞送技術的領先地位。2021年5月，心誠鎂與全球生物科技領導者CSL Behring共同進行血漿衍生免疫球蛋白的開發（CSL787）。團隊專注於吸入性藥械組合產品的開發，用於治療及緩解包含 慢性阻塞性肺病、氣喘、肺動脈高血壓、肺纖維囊腫及支氣管擴張症等呼吸道疾病，並藉此合作案正式將心誠鎂轉型為Drug-Device Combination product CDMO公司。 HCmed Innovations Co., Ltd. (HCmed) is founded in 2014 by a group of talents, who have dedicated themselves to the improvement of respiratory health for more than decades, with skills, knowledge, and passion. HCmed has been focusing on inhaled drug/device combination to ease respiratory diseases such us COPD, Asthma, PAH, CF, and Bronchiectasis. The innovative drug delivery system HCmed developed is aiming to trigger the efficiency of drug-device combination and optimize the inhalation therapy. As asthma, COPD and many respiratory diseases surge, what we want to fulfill, is not only a better therapy for our family and friends who suffer from those respiratory conditions, but also the cure and freedom for all in the future. By continuous improvement of science and technology, our diligent team strive to go beyond the borders and develop the cutting-edge solutions for clinical practice. HCmed is venture-backed with funding from Vivo Capital and other major investors from the US, Taiwan, and Japan. On Sept. 2019, HCmed was one of the first teams from around the world to be invited to join Wuxi International Life Science Innovation Park supported by AstraZeneca China, establishing HCmed's leading status in the respiratory drug delivery technology.